IsoPlexis’ Single-Cell Secretome Platform Powers Allogeneic CAR-T, AML Findings from Leading Researchers at ASH

Ahead of the American Society of Hematology (ASH) Annual Meeting & Exposition taking place from December 10th-13th, we are excited to highlight two upcoming poster presentations from Sana Biotechnology and University of Texas MD Anderson Cancer Center.

  • P# 1974; Functional T Cell Assays Are Predictive of Pre-Clinical Potency to Generate Allogeneic, Hypoimmune CD19 CAR T Cells
    Saturday, December 10, 2022, 5:30 PM-7:30 PM
  • P# 2788; Somatic Mutations in TP53 Identified in T-Cells of Patients with TP53-mutated AML
    Sunday, December 11, 2022, 6:00 PM-8:00 PM

IsoPlexis’ Single-Cell Secretome Platform is regularly leveraged for single-cell insights in cancer immunology research, identifying polyfunctionality of immune cells linked to disease, responding to disease, or engineered to treat disease. For example, several publications this year have highlighted its impact on blood cancers like acute lymphoblastic leukemia (ALL). In August, scientists from Beam Therapeutics* and Children’s Hospital of Philadelphia (CHOP) published data in Blood, using the platform to demonstrate the in vitro efficacy of a cytosine base-edited allogeneic CAR-T cell for T-cell ALL. And in June, a paper in Science Advances from CHOP, University of Pennsylvania, and Yale University researchers used single-cell functional analysis to identify biomarkers of CAR-T response and CD19-positive relapse in ALL.

This week at ASH, conference attendees can experience the IsoPlexis platform hands-on by visiting us at Booth #507. For more information, please visit our ASH Spotlight.


* This month, U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for BEAM-201 for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL)/T-cell lymphoblastic lymphoma (T-LL).

Share This Article
Subscribe to Follow the Data

Weekly email to keep you at the forefront of single-cell & multiplexed proteomics.